UroGen Pharma Aktie
WKN DE: A2DTCV / ISIN: IL0011407140
26.04.2025 18:28:15
|
UroGen Pharma Reports Positive Phase 1 Results For UGN-301 In Non-Muscle Invasive Bladder Cancer
(RTTNews) - UroGen Pharma Ltd. (URGN) announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC).
The company noted that UGN-301 demonstrated tolerability across all dose levels, with no dose-limiting toxicities or adverse events resulting in treatment discontinuation. The formulation of UGN-301 in a reverse thermal gel enabled sustained bladder exposure.
Additionally, some patients treated with UGN-301 (zalifrelimab) intravesical solution exhibited clinical activity during the week 12 disease assessment. These findings were presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu UroGen Pharma Ltd Registered Shsmehr Nachrichten
06.08.25 |
Ausblick: UroGen Pharma informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu UroGen Pharma Ltd Registered Shsmehr Analysen
Aktien in diesem Artikel
UroGen Pharma Ltd Registered Shs | 14,90 | -10,24% |
|